Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals

Leukemia

Volumn 14, Issue 4, 2000, Pages 602-611

  O'Gorman, D M ^a   McKenna, S L ^a   McGahon, A J ^a   Knox, K A ^b   Cotter, T G ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

AML; Apoptosis; Bcl 2 family; PI3 kinase; Ras

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; APIGENIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; WORTMANNIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL STRAIN HL 60; DRUG RESISTANCE; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SENSITIZATION;

EID: 0034033712     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401726     Document Type: Article

References (75)

1. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
2. O'Connor R. Survival factors and apoptosis. In: Scheper T (ed). Advances in Biochemical Engineering/Biotechnology, vol. 62. Springer-Verlag: Heidelberg, 1998, pp 137-166.
3. Senent L, Jarque I, Martin G, Sempere A, Gonzalez-Garcia Y, Gomis F, Perez-Sirvent M, De La Rubia J, Sanz MA. P-glycoprotein expression and prognostic value in acute myeloid leukemia. Haematologica 1998; 83: 783-787.
4. Legrand O, Zittoun R, Marie JP. Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia 1999; 13: 578-584.
5. Massaad-Massade L, Ribrag V, Marie JP, Faussat AM, Bayle C, Dreyfus F, Gouvette A. Glutathione system, topoisomerase II level and multidrug resistance phenotype in acute myelogenous leukemia before treatment and at relapse. Anticancer Res 1997; 17: 4647-4651.
6. McKenna SL, Padua RA. Multidrug resistance in leukaemia. Br J Haematol 1997; 96: 659-674.
7. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998; 8: 49-54.
8. Joneson T, Bar-Sagi D. Ras effectors and their role in mitogenesis and oncogenesis. J Mol Med 1997; 75: 587-593.
9. Rommel C, Hafen E. Ras - a versatile cellular switch. Curr Opin Genet Dev 1998; 8: 412-418.
10. McCormick F. Signal transduction. How receptors turn Ras on. Nature 1993; 363: 15-16.
11. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem 1998; 273: 19925-19928.
12. Quilliam LA, Khosravi-Far R, Huff SY, Der CJ. Guanine nucleotide exchange factors: activators of the Ras superfamily of proteins. Bioessay, 1995; 17: 395-404.
13. Wittinghoter A, Scheffzek K, Ahmadian MR. The interaction of Ras with GTPase-activating proteins. FEBS Lett 1997; 410: 63-67.
14. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
15. Byrne JL, Marshall CJ. The molecular pathophysiology of myeloid leukaemias: Ras revisited. Br J Haemotol 1998; 100: 256-264.
16. Friess H, Berberat P, Schilling M, Kunz J, Korc M, Buchler MW. Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J Mol Med 1996; 74: 35-42.
17. Demetri GD, Ernst TJ, Pratt ESD, Zenzie BW, Rheinwald JG, Griffin JD. Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. J Clin Invest 1990; 86: 1261-1269.
18. Gougopoulou DM, Kiaris H, Ergazaki M, Anagnostopoulos NI, Grigoraki V, Spandidos DA. Mutations and expression of the ras family genes in leukemias. Stem Cells 1996; 14: 725-729.
19. Price CM, Marshall CJ, Bashey A. Sequential acquisition ot trisomy 8 and N-ras mutation in acute myeloid leukaemia demonstrated by analysis of isolated leukaemic colonies. Br J Haematol 1994; 88: 338-342.
20. Weijzen S, Velders MP, Kast WM. Modulation of the immune response and tumor growth by activated Ras. Leukemia 1999; 13: 502-513.
21. Kinoshita T, Yokota T, Arai K, Miyajima A. Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene 1995; 10: 2207-2212.
22. Bensi L, Longo R, Vecchi A, Messora C, Garagnani L, Bernardi S, Tamassia MG, Sacchi S. Bcl-2 oncoprotein expression in acute myeloid leukemia. Haematologica 1995; 80: 98-102.
23. Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 1998; 9: 159-165.
24. Kinoshita T, Yokota T, Arai K, Miyajima A. Suppression of apoptotic death in hematopoietic cells by signalling through the IL-3/GM-CSF receptors. EMBO J 1995; 14: 266-275.
25. Minshall C, Arkins S, Freund GG, Kelley KW. requirement for phosphatidylinositol 3′-kinase to protect hemopoietic progenitors against apoptosis depends upon the extracellular survival factor. J Immunol 1996; 156: 939-947.
26. Scheid MP, Lauener RW, Duronio V. Role of phosphatidylinositol 3-OH-kinase activity in the inhibition of apoptosis in haemopoietic cells: phosphatidylinositol 3-OH-kinase inhibitors reveal a difference in signalling between interleukin-3 and granulocyte-macrophage colony stimulating factor. Biochem J 1995; 312: 159-162.
27. Franke TF, Kaplan DR, Cantley LC. P13K: downstream AKTion blocks apoptosis. Cell 1997; 88: 435-437.
28. Gajewski, TF, Thompson CB. Apoptosis meets signal transduction: elimination of a BAD influence. Cell 1996; 87: 589-592.
29. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998; 10: 262-267.
30. Cleveland JL, Troppmair J, Packham G, Askew DS, Lloyd P, Gonzalez-Garcia M, Nunez G, Ihle IN, Rapp UR. v-raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells. Oncogene 1994; 9: 2217-2226.
31. Wang HG, Miyashita T, Takayama S, Sato T, Torigoe T, Krajewski S, Tanaka S, Hovey Lr, Troppmair J, Rapp UR, Reed J. Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 1994; 9: 2751-2756.
32. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 1326-1331.
33. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994; 370: 527-532.
34. Kodaki T, Woscholski R, Hallberg B, Rodriguez-Viciana P, Downward J, Parker PJ. The activation of phosphatidylinositol 3-kinase by Ras. Curr Biol 1994; 4: 798-806.
35. Kinoshita T, Shirouzu M, Kamiya A, Hashimoto K, Yokoyama S, Miyajima A. Raf/MAPK and rapamycin-sensitive pathways mediate the anti-apoptotic function of p21Ras in IL-3-dependent hematopoietic cells. Oncogene 1997; 15: 619-627.
36. Chou MM, Blenis J. The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling. Curr Opin Cell Biol 1995; 7: 806-814.
37. Collard JC, van Beek WP, Janssen JW, Schijven IF. Transfection by human oncogenes: concomitant induction of tumorigenicity and tumor-associated membrane alterations. Int J Cancer 1985; 35: 207-213.
38. Hall A, Marshall CJ, Spurr NK, Weiss RA. Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature 1983; 303: 396-400.
39. Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S, Metzgar R, Aulakh G, Ting R, Ruscetti F, Gallo R. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979; 54: 713-733.
40. Gorman A, McCarthy J, Finucane D, Reville W, Cotter TG. Morphological assessment of apoptosis. In: Cotter TG, Martin SJ (eds). Techniques in Apoptosis, A User's Guide. Portland Press: London, 1996, pp 1-20.
41. Darzynkiewicz Z, Li X. Measurements of cell death by flow cytometry. In: Cotter TG, Martin SJ (eds). Techniques in Apoptosis, A User's Guide. Portland Press: London, 1996, pp 71-106.
42. D'Arpa P, Liu LF. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 1989; 989: 163-177.
43. Whitman M, Kaplan DR, Schaffhausen B, Cantley L, Roberts TM. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 1985; 315: 239-242.
44. Hoffbrand AV, Pettit JE. Acute Leukaemias: Essential Haematology, 3rd edn. Blackwell Scientific Publications: Oxford, 1993, pp 209-231.
45. Howard MR, Hamilton PJ. Haematology. Churchill Livingstone: Edinburgh, 1999.
46. Kuo ML, Yang NC. Reversion of v-H-ras-transformed NIH 3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes. Biochem Biophys Res Commun 1995; 212: 767-775.
47. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997; 275: 661-665.
48. Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, Hay N. The Pl 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 1997; 11: 701-713.
49. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 5241-5248.
50. Ui M, Okada T, Hazeki K, Hazeki O. Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase. Trends Biochem Sci 1995; 20: 303-307.
51. Duronio V, Scheid MP, Ettinger S. Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cell Signal 1998; 10: 233-239.
52. Ferrari S, Pearson RB, Siegmann M, Kozma SC, Thomas G. The immunosuppressant rapamycin induces inactivation of p70s6k through dephosphorylation of a novel set of sites. J Biol Chem 1993; 268: 16091-16094.
53. Franke TF, Cantley LC. Apoptosis. A Bad kinase makes good. Nature 1997; 390: 116-117.
54. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-291.
55. Chao JR, Wang JM, Lee SF, Peng HW, Lin YH, Chou CH, Li JC, Huang HM, Chou CK, Kuo ML, Yen JJ, Yang-Yen HF. mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response. Mol Cell Biol 1998; 18: 4883-4898.
56. Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 1997; 89: 630-643.
57. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, Reed JC. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998; 91: 991-1000.
58. Otter I, Conus S, Ravn U, Rager M, Olivier R, Monney L, Fabbro D, Borner C. The binding properties and biological activities of Bcl-2 and Bax in cells exposed to apoptotic stimuli. J Biol Chem 1998; 273: 6110-6120.
59. Hsu YT, Youle RJ. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J Biol Chem 1998; 273: 10777-10783.
60. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
61. Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB, Korsmeyer SJ. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 1995; 92: 7834-7838.
62. Hinton HJ, Welham MJ. Cytokine-induced protein kinase B activation and bad phosphorylation do not correlate with cell survival of hemopoietic cells. J Immunol 1999; 162: 7002-7009.
63. Scheid MP, Duronio V. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. Proc Natl Acad Sci USA 1998; 95: 7439-7444.
64. Kitada S, Krajewska M, Zhang X, Scudiero D, Zapata JM, Wang HG, Shabaik A, Tudor G, Krajewski S, Myers TG, Johnson GS, Sausville EA, Reed JC. Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines. Am J Pathol 1998; 152: 51-61.
65. Minn AJ, Kettlun CS, Liang H, Kelekar A, Vander Heiden MG, Chang BS, Fesik SW, Fill M, Thompson CB. Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms. EMBO J 1999; 18: 632-643.
66. Holmgreen SP, Huang DC, Adams JM, Cory S. Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members. Cell Death Differ 1999; 6: 525-532.
67. Ito T, Deng X, Carr B, May WS. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997; 272: 11671-11673.
68. May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA, Davidson NE. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J Biol Chem 1994; 269: 26865-26870.
69. Minshall C, Arkins S, Straza J, Conners J, Dantzer R, Freund GG, Kelley KW. IL-4 and insulin-like growth factor-1 inhibit the decline in Bcl-2 and promote the survival of IL-3-deprived myeloid progenitors. J Immunol 1997; 159: 1225-1232.
70. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA 1908; 95: 4386-4391.
71. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-1321.
72. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-868.
73. Widmann C, Gibson S, Johnson GL. Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. J Biol Chem 1998; 273: 7141-7147.
74. Plo I, Bettaieb A, Payrastre B, Mansat-De Mas V, Bordier C, Rousse A, Kowalski-Chauvel A, Laurent G, Lautier D. The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines. FEBS Lett 1999; 452: 150-154.
75. Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86: 685-691.